Endocrine Abstracts

Objectives: Antagonism of the IGF-1 receptor (IGF-1R) has been shown to reduce TED-related inflammation and proptosis. VRDN-001, a high-affinity antagonist antibody to IGF-1R, has distinct pharmacological properties that may enable differentiated dosing and better efficacy than observed with other antibodies. We assessed VRDN-001 in vitro pharmacology compared with teprotumumab and clinical proof of concept in a phase 1/2 randomized controlled trial (NCT05176639)....

Objective: Evidence shows that IGF-1 receptor (IGF-1R) antagonism reduces the inflammation and proptosis that occur in thyroid eye disease (TED). VRDN-001 is a full antagonist to IGF-1R, and VRDN-003 is a next-generation, half-life extended version of VRDN-001 designed to enable subcutaneous (SC) administration. We compared the in vivo pharmacokinetic (PK) parameters of VRDN-001 and VRDN-003 and used a PK model to simulate potential VRDN-003 SC dosing regimens.<p ...

Study objective: We investigated the effect of linsitinib, a dual small-molecule kinase inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and the Insulin receptor (IR), on Graves’ Disease and thyroid eye disease. Graves‘ disease (GD), also known as ‘Basedow’s disease‘, is the most common cause for hyperthyroidism, typically presenting in patients between 40-60 years. GD is an autoimmune condition of the thyroid which is caused by autoanti...

Background: Autoantibody mimicry of hormone action at the thyrotropin receptor (TSH-R) and aberrant signaling of TSH-R by autoantibodies (TSH-R-Ab) causes autoimmune thyroid disease (AITD), hyperthyroidism and hypothyroidism, both of which affect millions of patients worldwide. In this multicenter, single blind study, the specificity, sensitivity and performance of a novel bioassay for stimulatory TSH-R-Ab were tested.Methods: TSH-R-Ab were measured in a...

Objectives: Dysthyroid Optic Neuropathy (DON) is a severe complication of Graves’ Orbitopathy (GO), requiring prompt treatment. First line treatment is high dose intravenous steroids, then surgery is considered mandatory. We studied the clinical outcomes of surgery for DON, with and without previous therapy with steroids.Methods: 88 orbits of 56 patients with DON were treated with surgical orbital decompression. 33 orbits (37.5 %) underwent surgery ...